Most independent pharmacies that try compounding eventually stop.
Not because compounding does not work. Because the approach does not work.
There is a difference.
What usually happens
A pharmacy owner decides to add compounding.
They get certified. They acquire equipment. They put a flyer in the physician office across the street. They wait.
The volume does not arrive.
After a few months, compounding becomes an underused capability on a shelf. The investment sits idle. The owner concludes that compounding was not right for their market.
They have drawn the wrong conclusion from the right experience.
The conversation that changed one pharmacy
An independent pharmacy owner in a small Oklahoma town, population around 8,000, added compounding eighteen months after that exact decision point.
She did not market it broadly. She did not approach multiple physicians at once. She had one conversation with one dermatologist three miles away.
He mentioned, without urgency, that his patients were driving forty minutes for a topical formulation he prescribed regularly.
She said she would look into whether she could do it locally.
Four months later, she was compounding that formulation for sixty of his patients. At the time we spoke, she was compounding nine formulations for him and the two other physicians sharing his building.
Monthly gross margin from that single relationship: approximately $4,200.
Startup investment: approximately $18,000. Break-even: fourteen months.
"I wish I had done it five years ago," she said. "It is revenue that does not have a PBM anywhere near it."
That last sentence is the point.
Why the standard approach fails
Most pharmacies approach compounding as a service looking for demand.
Build the capability. Broadcast availability. Wait for the market to respond.
The market does not respond quickly enough. Not consistently enough.
The physician relationship model reverses this entirely.
It starts with a specific demand that already exists. It builds around one problem that one physician already has. It produces volume before the capability is fully scaled.
The difference is not clinical. It is commercial logic.
The physician specialties most likely to have this problem
Not every specialty generates consistent compounding demand. The categories that do are specific.
Dermatology
Topical formulations that commercial markets do not serve. Custom-strength preparations for individual patient needs. Combinations unavailable from commercial manufacturers.
The most common dermatology compounding formulas include tretinoin with niacinamide or azelaic acid, customized-strength hydroquinone preparations, and topical scar or pain management compounds.
This is the strongest starting category for most independent pharmacy markets. Find the dermatologist first.
Pain management
Transdermal compounds. Customized dosing for patients intolerant of standard formulations. Low-dose naltrexone preparations.
Patient populations in pain management tend to be chronic condition patients. That means referral volume from a single relationship is both substantial and predictable over time.
Integrative medicine and hormone therapy
Bioidentical hormone preparations are the primary compounding category. Patient populations in these practices tend to be cash-pay oriented and already committed to individualized care.
Pediatric primary care
Children who cannot swallow tablets. Antibiotics and antifungals with no commercial pediatric liquid formulation available. Consistent, predictable volume from a small patient panel.
This is an underused opportunity. Physicians refer automatically once established, because the alternative is no good commercial option at all.
Veterinary medicine
Animals with dosing requirements that commercial products cannot meet. A market that chain pharmacies almost never compete in. Requires additional regulatory consideration but follows the identical commercial logic.
The pattern in every category is identical.
A recurring, specific patient need. A commercial market that addresses it inadequately. A physician who has made peace with the gap because they did not know a local solution existed.
Your job is to surface that conversation.
The full process
Step 1 — Research before you reach out
Before approaching any physician, understand what they commonly prescribe and where commercial options fall short.
Professional compounding organizations publish reference materials on common formulas by specialty. The American College of Apothecaries and the Professional Compounding Centers of America both produce this material in the US context.
The goal is arriving at the first conversation knowing specifically what you can offer — not in general terms, but in the formulation categories that match their exact practice type.
Step 2 — Make first contact through a warm channel
The cold walk-in to a physician office is the least effective approach.
It positions you as a vendor. Physicians talk to vendors all day. They do not remember most of them.
The channels that carry trust carry the conversation differently.
A mutual patient who mentions their pharmacist to their physician. A hospital pharmacist who introduces you. A county medical society or CE event where you are both present as professionals.
If none of those options exist, a brief written letter that leads with a specific clinical question outperforms a walk-in every time.
Step 3 — Open with their problem, not your capability
The first question that consistently opens these conversations is simple.
"Are there patients you see regularly where the available commercial formulations are not quite right for what they need?"
That question invites the physician to describe a problem.
Your compounding capability is the answer to their problem. It is not the introduction to the conversation.
Physicians are not interested in your equipment list. They are interested in their patients. Start there.
Step 4 — Solve one thing first
Resist the impulse to address every compounding need at once.
Identify the single formulation that represents their most frequent, most straightforward need. Compound it for the specific patients best suited to it. Do it flawlessly.
A physician who has one very good experience with a compounding pharmacist will expand the relationship without being asked. They will mention you to colleagues without being prompted.
One perfect delivery is worth more than ten adequate ones.
Step 5 — Document carefully and know your regulatory limits
Compounding for specific patients on valid prescriptions from licensed practitioners is a defined regulatory category.
Staying within that framework protects both your pharmacy and the physician relationships you are building.
Your state board of pharmacy is the primary authority in the US context. Their published compounding guidance is the baseline standard. If you are uncertain about a specific formulation or practice, contact the board before proceeding.
What the revenue actually looks like
The Oklahoma case is not an outlier in structure. Specific numbers vary by market and formulation category.
A single dermatology relationship, once established, typically generates between $2,000 and $5,000 per month in gross margin.
A pediatric compounding relationship with three primary care physicians in Texas was generating approximately $3,100 per month. The pharmacist described it as almost entirely self-sustaining. "The physicians referred automatically because they had no alternative."
Gross margins on compounded preparations typically range from 40 to 70 percent. That compares favorably to commercial dispensing margins in most Part D reimbursement environments.
The startup investment for basic non-sterile compounding typically runs between $10,000 and $25,000.
At a $3,000 monthly gross margin contribution, that investment recoups in four to eight months.
The revenue continues after that with relatively low ongoing fixed cost.
How to price your formulations
Compounded medications are generally not reimbursed by standard insurance plans.
This is an advantage, not a limitation.
Pricing is a direct calculation between your costs, your market, and the value you are providing — not a rate set by an intermediary whose interests do not align with yours.
Calculate ingredient cost plus direct labor and overhead for the specific formulation. Apply a professional service markup that reflects the clinical value, the regulatory compliance, and the customization involved.
Gross margins typically range from 40 to 70 percent.
The most productive pricing research is understanding what patients currently pay for the commercial alternatives you are replacing. Physicians will tell you this if you ask.
When a physician is not interested
This will happen.
Not every physician has pressing compounding needs. Not every physician who has those needs will engage on the first conversation.
The pharmacist in Oklahoma approached two physicians before the dermatologist. Neither expressed significant interest. The third conversation became a $4,200 per month revenue stream.
This is not a process that usually succeeds on the first attempt.
It is a process that consistently succeeds when pursued with patience, specific preparation, and genuine orientation toward the physician's patient problem rather than your pharmacy's revenue goal.
The strategic point that matters most
Every dollar from a compounding relationship is a dollar that does not depend on a PBM contract, a DIR reconciliation, or a Part D reimbursement rate.
Over time, building multiple revenue streams of this kind changes the risk profile of the entire business.
That is not a margin calculation. That is a structural change.
And it is available to any independent pharmacy with a qualified pharmacist, access to one physician with a recurring patient need, and the discipline to approach that physician with a specific solution rather than a general pitch.
What to do this week
Identify one physician in your area whose specialty suggests compounding need. Dermatology is the most accessible starting point for most markets.
Spend ninety minutes researching the specific formulation categories that specialty needs and that commercial options serve poorly.
Identify a warm channel for first contact, or draft a brief letter that opens with a clinical question rather than a service pitch.
That is the entire beginning. The rest follows from that first conversation.
Read next on Blinkerhub:
If reimbursement pressure is the reason building non-PBM revenue matters so urgently, the full breakdown of what DIR fees are and what the 2024 reform actually changed is worth reading before you build your next year's financial plan.
If you want a second revenue stream that also operates entirely outside PBM contracts — and requires no capital investment at all — the MTM billing guide covers exactly that.
And if the bigger question of whether to keep building an independent pharmacy business is what you need answered first, we have answered it directly and without the trade press optimism.
Blinkerhub is a free weekly intelligence newsletter for independent pharmacy owners worldwide. Not affiliated with any PBM, chain pharmacy, trade association, or pharmacy software vendor. Published every Tuesday at pharmacy.blinkerhub.com.
The regulatory requirements for pharmaceutical compounding vary by jurisdiction. Consult your state or national board of pharmacy before beginning a compounding program.